The size of the Asia-Pacific Advanced Infusion Systems Market is forecasted to be growing at a healthy CAGR between 2021 to 2026.
Infusion systems are medical instruments and disposables, which are used to distribute fluids or administer drugs in the form of a solution to the patient’s circulatory system in a precise, controlled, and systematic manner. The most used mode is through intravenous, although arterial, subcutaneous, and epidural infusion is more favorable. This instrument was widely used for medicinal purposes but because of high mortality rates associated with it, advanced infusion systems were developed.
Advanced Infusion Systems are a class of drug delivery devices that have found extensive acceptance and usage across various areas. These pumps have bolstered their position in a wide range of application areas including diabetes, oncology, enteral feeding pain management, and general infusion. Features like visual monitoring, easy start up, mobility of system, steady and continuous infusion of multiple drugs at the same time, patient safety some of the major factors that are furthering the growth of the potential market of advanced infusion systems over conventional ones.
The growth in this market is largely driven by the increasing incidence of cancer, diabetes and chronic diseases owing to the rising geriatric population. Immensely developed technology in infusion systems which eliminates user-related risks, safety, therapeutic effectiveness, higher bioavailability, increase in healthcare spending are also some other factors that propel the growth of the market. However, to operate these advanced infusion systems, extensive training is required. The presence of strict regulations for product approval and possible medication errors associated with infusion pump may restrain the growth of the market during the forecast period.
Asia-Pacific Advanced Infusion Systems Market is segmented based on type of application, type of product and end-users. Applications are segmented into Clinical Nutrition, Chemotherapy, Pain Management, Diabetes and Asthma Treatment. Product type is segmented into Disposable Infusion System, Elastomeric Infusion System, Ambulatory Infusion System, Volumetric Infusion System, Patient Controlled Analgesia Pump, Syringe Infusion System and Implantable Infusion System. End-users has been further segmented as Diagnostic Centers, Hospitals and Ambulatory Surgical Centers. Futhermore, based on geography the market is segmented into various regions namely Japan, China, India, South Korea and Australia. North America commands the largest regional segment of the global advanced infusion systems market. Asia-Pacific countries, particularly China and India) are expected to offer substantial growth opportunities for market players in the forecast period owing due to the huge patient population, increasing incidence of chronic diseases with changing lifestyles, improving healthcare facilities, increasing accessibility to advanced products, and increasing disposable income.
Hospira, Inc., is a market leader in infusion technologies globally. The major players in these markets are AngioDynamics, Inc., Medtronic, Inc., Terumo Corporation, Johnson & Johnson, CareFusion Corporation, Animas Corporation, Baxter International, Inc., B. Braun Melsungen AG, I-Flow Corporation, and F. Hoffmann-La Roche Ltd.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Clinical Nutrition
5.1.3 Chemotherapy
5.1.4 Pain Management
5.1.5 Diabetes
5.1.6 Asthma
5.1.7 Y-o-Y Growth Analysis, By Application
5.1.8 Market Attractiveness Analysis, By Application
5.1.9 Market Share Analysis, By Application
5.2 Product
5.2.1 Introduction
5.2.2 Disposable Infusion System
5.2.3 Elastomeric Infusion System
5.2.4 Ambulatory Infusion System
5.2.5 Volumetric Infusion System
5.2.6 Patient Controlled Analgesia Pump
5.2.7 Syringe Infusion System
5.2.8 Implantable Infusion System
5.2.9 Y-o-Y Growth Analysis, By Product
5.2.10 Market Attractiveness Analysis, By Product
5.2.11 Market Share Analysis, By Product
5.3 End-User
5.3.1 Introduction
5.3.2 Diagnostic Centers
5.3.3 Hospitals
5.3.4 Ambulatory Surgical Centers
5.3.5 Y-o-Y Growth Analysis, By End-User
5.3.6 Market Attractiveness Analysis, By End-User
5.3.7 Market Share Analysis, By End-User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product
6.1.3.4 By End-User
6.1.4 Market Attractiveness Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product
6.1.3.4 By End-User
6.1.5 Market Share Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product
6.1.3.4 By End-User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Hospira, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AngioDynamics, Inc.
8.3 Medtronic, Inc.
8.4 Terumo Corporation
8.5 Johnson & Johnson
8.6 CareFusion Corporation
8.7 Animas Corporation
8.8 Baxter International Inc.
8.9 B. Braun Melsungen AG
8.10 I-Flow Corporation
8.11 F. Hoffmann-La Roche Ltd
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
